Download this free whitepaper to learn more.
Precision oncology has advanced rapidly, but real-world outcomes often fall short of expectations. This white paper explores the disconnect between controlled trial data and how cancer is actually diagnosed and treated in practice—where variability in testing, treatment sequencing, and patient populations can significantly impact results.
By integrating multimodal real-world data—including molecular, clinical, and longitudinal insights—teams can generate a more complete and representative view of the patient journey. This approach supports better decision-making across development, evidence generation, and access, reducing uncertainty and aligning strategies with real-world oncology care.
Access now to learn about:
- Why trial data alone isn’t enough
- Reasons real-world variability matters
- How multimodal data adds critical context
- Strategies for improving study design, feasibility, and overall strategy across the lifecycle
- The expanding use of real-world evidence in development and access decisions
Offered Free by: NeoGenomics
See All Resources from: NeoGenomics
